4.2 Article

Neurosteroid binding to the amino terminal and glutamate binding domains of ionotropic glutamate receptors

Journal

STEROIDS
Volume 77, Issue 7, Pages 774-779

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.steroids.2012.03.011

Keywords

iGluR; Amino terminal domain; Pregnenolone sulfate; Pregnanolone sulfate

Funding

  1. NSF [CAREER-MCB-0447541, RUI-MCB-1049954, MRI-0722600]
  2. University of Richmond
  3. Div Of Molecular and Cellular Bioscience
  4. Direct For Biological Sciences [1049954] Funding Source: National Science Foundation

Ask authors/readers for more resources

The endogenous endogenous neurosteroids, pregnenolone sulfate (PS) and 3 alpha-hydroxy-5 beta-pregnan-20-one sulfate (PREGAS), have been shown to differentially regulate the ionotropic glutamate receptor (iGluR) family of ligand-gated ion channels. Upon binding to these receptors, PREGAS decreases current flow through the channels. Upon binding to non-NMDA or NMDA receptors containing an GluN2C or GluN2D subunit, PS also decreases current flow through the channels, however, upon binding to NMDA receptors containing an GluN2A or GluN2B subunit, flow through the channels increases. To begin to understand this differential regulation, we have cloned the 5152 and amino terminal domains (ATD) of the NMDA GluN2B and GluN2D and AMPA GluA2 subunits. Here we present results that show that PS and PREGAS bind to different sites in the ATD of the GluA2 subunit, which when combined with previous results from our lab, now identifies two binding domains for each neurosteroid. We also show both neurosteroids bind only to the AID of the GluN2D subunit, suggesting that this binding is distinct from that of the AMPA GluA2 subunit, with both leading to iGluR inhibition. Finally, we provide evidence that both PS and PREGAS bind to the S1S2 domain of the NMDA GluN2B subunit. Neurosteroid binding to the S1S2 domain of NMDA subunits responsible for potentiation of iGluRs and to the ATD of NMDA subunits responsible for inhibition of iGluRs, provides an interesting option for therapeutic design. (C) 2012 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available